This is an abbreviated version of Battea’s Insys Therapeutics securities litigation proprietary research. Full case summaries and economic analyses are available to clients through Battea’s litigation monitoring portal. For more information, or to request a demonstration, contact Battea.
Case Filed: March 17, 2017
Securities class action on behalf of a class consisting of all persons other than defendants who purchased or otherwise acquired Insys securities between February 23, 2016 and March 15, 2017, pursuant to sections 10(b) & 20(a) of the Securities Exchange Act of 1934. To read more about the Insys Therapeutics securities litigation, visit Battea's Insys Therapeutics news article.
|Lead Plaintiff Deadline||5/16/2017
The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) Insys had overstated its 2015 net revenue; (2) Insys had misstated its sales allowances for 2016; (3) accordingly, the company lacked effective internal controls over financial reporting; and (4) as a result, Insys's public statements were materially false and misleading.
Brief Company Profile
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients. The company is headquartered in Chandler, Arizona.
|Class Period||2/23/16 - 3/15/17
|Court||S.D. New York
|Judge||Hon. Paul A. Crotty
|Defendant(s)||INSYS THERAPEUTICS, INC., SANTOSH J.
VETTICADEN and DARRYL S. BAKER
Insys Therapeutics Securities Litigation Price Chart